NTHI - NASDAQ
Neonc Technologies Holdings, Inc.
$4.43
+1.8%Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
At a Glance
Live Snapshotnthi
Research Development Expenses
Last Annual Value
3.64M
3-Year CAGR
46%
5-Year CAGR
40%
10-Year CAGR
18%
Neonc Technologies Holdings, Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Neonc Technologies Holdings, Inc. NASDAQ:NTHI | 3.64M | 33.4% | 40.1% | N/A | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 23.72M | -11.1% | 3.5% | 15.4% | |
 Invivyd, Inc. NASDAQ:IVVD | 38.31M | -37.7% | -26.8% | N/A | |
 OmniAb, Inc. NASDAQ:OABI | 47.75M | -5.5% | 4.0% | N/A | |
 SELLAS Life Sciences Group, Inc. NASDAQ:SLS | 16.02M | -12.6% | -5.6% | -2.1% | |
 Assembly Biosciences, Inc. NASDAQ:ASMB | 64.81M | 9.8% | -1.1% | 7.0% | |
 Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | 70.09M | 31.0% | 14.0% | 16.3% | |
 Genelux Corporation NASDAQ:GNLX | 19.85M | 15.9% | 25.7% | N/A | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 112.67M | -21.6% | -13.4% | 5.6% | |
 Protara Therapeutics, Inc. NASDAQ:TARA | 42.63M | 19.8% | 15.1% | 8.5% | |
 Orchestra BioMed Holdings, Inc. NASDAQ:OBIO | 58.19M | 19.8% | 35.2% | N/A |
Neonc Technologies Holdings, Inc. Fair Value Envelope
Related Guides
Continue your NTHI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.